Compare HubSpot Inc (HUBS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Novo Nordisk A/S — how do they compare? HubSpot Inc trades at $218 (market cap $11.84B), while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 18.6× HubSpot Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals.
| HUBS | NVO | |
|---|---|---|
Market Cap | $11.84B | $220.53B |
Sector | Technology | Health |
52-Week High | $560.90 | $71.70 |
52-Week Low | $170.39 | $35.29 |
Enterprise Value | $10.39B | $239.49B |
Dividend Yield | — | 3.63% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
